Re:Re: NAC(N-Acetyl cysteine)의 항산화, 항암, 항바이러스 효과 reiew

[문형철]

beyond reason

현대의학의 선배 탐구자에게 감사와 존경을

NAC는 강력한 항산화 물질인 글루타치온의 전구물질.

poly cystic ovary syndrome patients with CC resistance, preterm birth, acetaminophen toxicity, RPL, chronic bronchitis, ulcerative colitis, liver cancer, muscle performance, hemodialysis, asthma, Alzheimer and Parkinson 

Introduction

N-acetyl cysteine (NAC), as a safe and inexpensive medication, is commercially accessible since long-time ago (1). This drug is not found in natural sources, although cysteine is present in some meals like chicken and turkey meats, garlic, yogurt, and eggs (2). NAC is a well-tolerated mucolytic drug that moderates clinging mucous secretions and enhances glutathione S-transferase activity. During oral administration, deacetylation reaction of NAC happens while passing along the small intestine as well as liver, thus its bioavailability is decreased to 4-10%. NAC stimulates glutathione biosynthesis, promotes detoxification, and acts directly as a scavenger of free radicals. It is a powerful antioxidant and a potential treatment option for diseases characterized by the generation of free oxygen radicals (3). Studies have shown no maternal or fetal harmful effects of NAC treatment. This nutritional supplement is an excellent source of sulphydryl groups. NAC prevents apoptosis and oxygen related genotoxicity in endothelial cells by increasing intracellular levels of glutathione and decreasing mitochondrial membrane depolarization (4). The critical antioxidant power of NAC is due to its role as a precursor of glutathione, which is one of the most important naturally occurring antioxidants (5). NAC combination with vitamin E, or vitamins A+E, as well as essential fatty acids considerably reduce reactive oxygen species (ROS), leading to pregnancy rate improvement (6). Studies have indicated that preserving impact of NAC against the toxicity of chemicals is due to its dual role as a nucleophile and as a -SH donor (7). In this study by reviewing literatures, various applications of NAC in treatment of some diseases are highlighted. 

Polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrine glands-related diseases affecting 5-10% of reproductive-age women (8). This syndrome is considered as the most common cause of anovulatory infertility. PCOS is also associated with pregnancy complications such as recurrent pregnancy loss (RPL). Different studies report the preval‎ence of PCOS in women with a history of RPL in a wide range of 10-82%. Findings show that 70.7% of PCOS women with a previous RPL had thrombophilic disorders. In addition, preval‎ence of protein C deficiency is significantly higher in PCOS patients compared to the non-PCOS women (9). 

The results of a study showed that women with PCOS have a high preval‎ence of metabolic syndrome and its individual components (obesity, hypertension, glucose intolerance and triglycerides), particularly decreased high density lipoprotein cholesterol (10). In another study, women and their relatives with PCOS had an increased preval‎ence of diabetes commonly in mother’s side of the family (11). 

As the first medication option, clomiphene citrate (CC) is applied for the induction of ovulation in PCOS women. A collection of published results for treatment with CC showed a pregnancy rate and a miscarriage rate of 36 and 20.4%, respectively. One of the frequently determined problems of this treatment is resistance to CC in up to 40% of PCOS patients. NAC is a mucolytic drug with insulin-sensitizing properties that has been used successfully as a supporting therapy in subjects with CC-resistant PCOS (8). Recent studies have shown that a combination of CC and NAC considerably increased both ovulation and pregnancy rates in women with CC-resistant PCOS. NAC has multiple biological effects, two of which are potentially and directly related to pregnancy rate improvement. NAC has mucolytic action, thus it can revoke the negative effect of CC on cervical mucus. Simultaneously, it has insulin sensitizing effect that could assist in issues related to PCOS. The negative influence of CC on cervical mucus can create a "hostile" environment for conception (1). 

Researchers eval‎uated the effect of NAC, known to resupply stores of the antioxidant glutathione, on insulin secretion and peripheral insulin resistance in subjects in association with PCOS. Moreover, treatment of hyperinsulinemic patients by NAC was found to tailor control parameters of glucose in them and consequently, their insulin levels and peripheral insulin sensitivity were reduced and increased, respectively. Therefore, the antioxidant effects of NAC may act as a therapeutic approach to improve the level of circulating insulin as well as insulin sensitivity in PCOS patients with hyperinsulinemia (12). 

Premature birth and recurrent pregnancy loss

Premature birth is the most common reason of perinatal mortality and long-term unhealthiness in low-income countries (13). Inflammation, fetal infection, and previous preterm delivery are significant risk factors for preterm birth and neonatal brain injury (14). Rising infection with bacterial vaginosis during pregnancy is related to a risk factor for preterm delivery and low birth weight. Antimicrobial medical care is, although, not adequate for the prevention of preterm birth and the inflammatory as well as anti-inflammatory responses could make problem complex (3). NAC by having an anti-inflammatory outcome can affect human term and preterm labors. NAC restrains the inflammatory response with no respect whether infection is started before or after treatment initiation with the drug. Shahin et al. (3) concluded that in women with previous preterm birth and bacterial vaginosis, 0.6 g of NAC daily can be taken orally along with progesterone after week 16 of pregnancy to protect against preterm birth recurrence and improve neonatal outcome. 

RPL is defined as the occurrence of three or more consecutive pregnancy losses in the first or early second trimester of pregnancy (less than 20 weeks of gestation). It is one of the most common clinical problems in reproduction that a certain cause can be found in only 50% of cases (15). Many etiologies have been suggested for RPL (16). For example, molecular genetic background for RPL is being increasingly understood, and some polymorphisms associated with RPL have been reported. According to the research directed up to now, more than 40 gene products distinctively have been distinguished to be expressed in women with RPL compared to healthy women. These genes may have regulatory roles in establishing or maintaining normal pregnancy. In this manner, any nucleotide modifications in targeted genes may result in distinct expression‎ and activity endangering general well-being during pregnancy. A recent study showed a relationship between c.179A>C mutation in the Bax promoter and RPL and also, two polymorphisms, namely c.90G>C and c.95G>A in exon 1, found among patients that can be considered as genetic factors making people susceptible to miscarriages (17). Findings of the other recent study revealed a new genetic relationship between occurrences of RPL and SULF1 gene mutation. SULFs are a protein family of arylendosulfatase. They act as post synthetic editors that can selectively release 6-O-sulfate groups from heparin sulfates, consequently changing the sulfation patterns of proteoglycans and binding site of many growth factors. With such unique regulatory activity, SULFs have an important role in many biological processes, such as angiogenesis, cell signaling and embryogenesis. In this gene family, SULF1 is expressed in the large number of embryonic and adult tissues, while it has an important role in viability and embryonic development (18). In a study conducted by some researchers, high rate of mutations in D-loop of mtDNA was observed in maternal blood, a fact that may have a direct or indirect role in inducing RPL. This outcome can be utilized as part of the RPL eval‎uation, planning conceivable medications for enhancing the results of assisted reproduction (19). Some evidence has shown that oxidative stress might be a contributory factor in RPL (16). One phenomenon that is known as a common patho-physiological pathway for various etiologies of RPL, can be placental oxidative stress. Amin concluded that NAC is a well-tolerated drug that could potentially be an effective treatment in patients with unexplained RPL. Administration of a combination of NAC and folic acid, in comparison with folic acid alone, is resulted in prolongation of a living pregnancy up to 20 weeks. In addition, combination of NAC and folic acid were also associated with a significant increase in the take-home baby rate, as compared to folic acid alone (4). 

Acetaminophen toxicity

Acetaminophen administration is reported as the most common drug overdose in pregnancy. Acetaminophen readily crosses the placenta and in toxic doses can result in fetal hepatic necrosis, premature birth, spontaneous abortion, and fetal death (2). NAC is an amino acid that contains thiol group. It has been used for the treatment of acetaminophen toxicity (20). N-Acetyl-pbenzoquinonimine is a potent oxidative metabolite of acetaminophen, resulting in hepatotoxicity, if it is not reduced by glutathione. NAC is thought to affect through multiple mechanisms including replenishing glutathione, reducing N-acetyl-pbenzoquinonimine directly, and performing nonspecific hepatoprotective actions related to its antioxidant properties. This compound is used to treat acetaminophen poisoning throughout pregnancy (3). It is universally effective to prevent hepatotoxicity, if it is administrated within 10 hours of acetaminophen overdose (21). 

In addition, acetaminophen toxicity is a common cause of drug-induced hepatotoxicity in children and adults. NAC has been used for several decades and it has been proven as a counterpoison choice in treating acetaminophen-induced hepatotoxicity. There is considerable clinical evidence to support the fact that oral and intravenous NAC are equally effective in the prevention of hepatotoxicity. An important factor in eval‎uating the effectiveness of NAC is the timing of therapy commencement in relation to the administration. Patients that ingest a severe overdose and have NAC therapy started within 8 hours get well and have less than a 10% rate of occurrence of hepatotoxicity. They generally do not develop liver failure or death. Those patients who have chronically taken immoderate doses of acetaminophen over many hours and/or have NAC therapy started more than 8 hours after an acute overdose are at a risk of hepatotoxicity with approximately 8-50% incidence (22). 

Several recent studies have investigated the antioxidant properties of NAC in feto-placental metabolism (23,24). NAC appears to attenuate placental production of inflammatory cytokine interleukin 6 involved in placenta infection and inflammation in the pregnant rat model. A murine model demonstrated benefit of NAC in a complicated pregnancy, manipulated by infection and free radical production, suggesting the ability of NAC to restore maternal and fetal oxidative balance to reduce preterm birth caused by different factors such as acetaminophen toxicity (21). 

In vitrostudies have shown that oxidative stress might serve as a signal to initiate and propagate the inflammatory process, resulting in apoptosis of placental tissues (6). Bloosesky et al. (25) showed that preventative effect of NAC could reduce fetal inflammatory cytokines in response to maternal lipopolysaccharide. Their results suggested that prophylactic NAC administered in pregnancies was associated with a risk of maternal infection/inflammation, likely protecting fetus from adverse inflammatory sequelae. 

Administration of N-acetyl cysteine for infertile patients undergoing assisted reproductive

techniques Elgindy et al. (5) found that 1200 mg NAC (daily) supplementation, started with administration of human menopausal gonadotrophin till the day of human chorionic gonadotrophin, did not significantly increase pregnancy rate in intracytoplasmic sperm injection (ICSI) cycles using the long agonist protocol. NAC treatment was associated with insignificant decrease in granulosa cell apoptosis, as well as insignificant increase in fertilization rate and grade-one embryo formation. Larger-scale studies, possibly with higher doses and/or longer duration of NAC administration, should be performed to identify any significant effects. In addition, Cheraghi et al. (26) conducted a study to determine the effect of co-administration of NAC and metformin on ovulation induction in PCOS patients with ICSI cycle. They detected that co-administration of these two components has no benefit for ovulation induction in PCOS patients with ICSI cycle. In another study, Rizk et al. (27) investigated the effect of NAC on performance of CC in ovulation induction. They concluded that the combination of NAC with CC is an effective way for ovulation induction in young women undergoing ICSI cycles. 

Chronic bronchitis

Chronic bronchitis is defined as the presence of chronic productive cough for more than three months in each of two sequential years. Therefore, an important goal in the treatment of chronic bronchitis is to decrease the frequency and duration of intensification, and to decrease symptoms in patients with aggravations. In some European countries, mucolytic drugs, particularly NAC may be used as an anti-inflammatory drug as well as an antioxidant (28,29). In these countries, it is believed that NAC can decrease the frequency of aggravations and improve symptoms in patients with chronic bronchitis. Recently, a comprehensive review in literature survey has concluded in the field of the effectiveness of any oral mucolytic drugs that a decline of aggravations, days of disability and days of antibiotic treatment was averagely determined in patients with chronic clogging pulmonary disease (30). 

Ulcerative colitis

Ulcerative colitis is a chronic inflammatory disorder which multiple casual factors can affect it. Human colitis has many similar characteristics to acetic acid (AA)-induced colitis, as a reproducible and simple model. Studies have indicated that some signaling pathways contributing in cell apoptosis and growth, angiogenesis, redoxregulated gene expression‎, and inflammatory response can be affected by NAC (6,31,33). Therefore, NAC may not only protect against the direct detrimental impacts of oxidants, but also advantageously modify inflammatory events in colitis (34). The beneficial influences of NAC were related to the changes including: i. Softened colonic injury, ii. Decreased oxidative stress, iii. Lowered cell apoptosis, iv. Increased recovery of the injured colon, and v. Increased formation of the tight junction (6). 

Liver cancer

Liver cancer is one of the most common lifethreatening malignancies, all over the world and up to now, there is no effective drug for the treatment of liver tumors (35). Although, interferon (IFN) is the most applied medication in chronic hepatitis and hepatocarcinoma, due to its immune response activation property and also regulation of differentiation and cell growth (36). NAC, as an enhancer of glutathione biosynthesis (37), is one of the frequently used antioxidant drugs for treatment of liver disorders (38,39). Cell culture and animal models have shown that NAC can preserve normal cells against toxicity of radiotherapy and chemotherapy, but not cancerous cells (37). Administration of NAC may play a role in treatment of some forms of cancer, while induced damages in DNA can be completely blocked by NAC (38). 

Muscle performance

Investigations showed no effect of NAC on nonfatigued muscle, although after three minutes of repetitive contractions, it caused a considerably enhanced force output, up to approximately 15%. This means that NAC can improve muscle performance. This result is originated from the fact that oxidative stress plays a causal role in the fatigue process, since NAC is a scavenger of free radicals causing oxidative stress. It has been wellreported that infusion of NAC can be effective on enhancing the overall redox status in vivo. It has also been shown that NAC infusion could minimize the muscle fatigue (40). 

Hemodialysis

Homocysteine (Hcy) is a sulphur-containing amino acid that is produced in body, by the metabolism of the methionine amino acid (41). Hcy level in patients with hemodialysis is associated with kidney-related disorders. However, in the treated hemodialysis patients, some studies have shown that NAC administration could affect plasma Hcy levels. There are some reports indicating that NAC, with an antioxidant property, has declined plasma Hcy level in the end stage renal disease (ESRD) patients undergoing hemodialysis. Although, lower dosage of NAC (for example, 600 mg/day for a period of one month) could not help to decrease Hcy plasma levels in these patients (42). 

Asthma

Asthma is a chronic disorder associated with inflammation and immune cell infiltration of airways (43). Airway hyper-responsiveness (AHR) can be originated from consistent presence of inflammatory mediators and immune cells in airways. AHR is clinically determined with breathlessness, coughing and wheezing symptoms (44). Studies showed the preventive effect of NAC antioxidant on the AHR and steroid resistant accumulation of inflammatory cells in the airways of the animal model with acute exacerbation of asthma (45,47). 

Alzheimer

Alzheimer disease (AD) is known as a multifactorial disease with many abnormalities in physiological, biochemical, and neurochemical point of view. Aging is the major risk factor for AD that coexists with other causes of cognitive decline, particularly vascular dementia (48). Some factors, such as mitochondrial dysfunction, abnormal protein aggregation, metal accumulation, inflammation and excitotoxicity play important roles in AD pathology. Although the relationship between these factors and development of AD is multidirectional, oxidative damage is considered as a common thread linking some of these factors (49). Results of different studies showed that lipoic acid (LA) and NAC decreased levels of oxidative and apoptotic markers via protection of mitochondrial function (50,53). Combination of both LA and NAC maximizes this protective effect suggesting that this may prevent mitochondrial decay associated with aging and age-related disorders such as AD. Antioxidant therapies based on LA and NAC seem promising since they can act on mitochondria, one key source of oxidative stress in aging and neurodegeneration (50). 

Parkinson

Parkinson disease (PD) is a very preval‎ent neurodegenerative disorder caused by unknown deterioration of cells which generate dopamine in the pars compacta, a part of the substantial nigra located in the midbrain (54). In terms of pathogenesis, PD appears to be multi-factorial disorder, including environmental factors, acting on genetically vulnerable individuals when they are older (55,56). A wide range of both genetic and environmental factors have been proposed as contributing to the initiation and progression of PD, but aging is the single most important risk factor for this disorder and undoubtedly interferes in PD progression through its accumulative oxidative damage, decrease in antioxidant ability and impairment of mitochondrial bio-energetic capacity in the brain (57,58). Taking into account that most of PD patients experience accumulative oxidative damage, some clinical studies have demonstrated the controversial effect of some antioxidant administrations -such as NACon treatment of PD (59,61). Some improvements have been reported for systemic administration of NAC in animal models, such as: i. Enhancement of brain level of glutathione, ii. Reduction of oxidative damage-markers, iii. Enhancement of brain synaptic and non-synaptic brain mitochondrial complex I activities, and iv. Protection against dopamine-induced cell death (59). 

Go to:

Conclusion

A review on NAC literature shows that this agent is a safe and well-tolerated supplementary drug without any considerable side effects. It 16 is as an antioxidant with a free radical scavenger property, as important characteristic of this medical supplement. It has been used as a beneficial drug treatment for some disorders such as poly cystic ovary syndrome patients with CC resistance, preterm birth, acetaminophen toxicity, RPL, chronic bronchitis, ulcerative colitis, liver cancer, muscle performance, hemodialysis, asthma, Alzheimer and Parkinson. Although in some cases, such as improving pregnancy rate in ICSI cycles, NAC action is still unclear and further investigations are necessary. 

Go to:

Acknowledgments

The authors would like to thank Royan Institute experts for their helpful comments and suggestions. There is no conflict of interest in this study. 

Go to:

References

1. Youssef G, Meguid Ali A, Alaa N, Makin B, Waly M, AbouSetta A. N-acetyl-cysteine in anovulatory women: the impact of postcoital test. Middle East Fertil Soc J. 2006;11:109–112. [Google Scholar]

2. Larsson SC, Håkansson N, Wolk A. Dietary cysteine and other amino acids and stroke incidence in women. Stroke. 2015;46(4):922–926. [PubMed] [Google Scholar]

3. Shahin AY, Hassanin IM, Ismail AM, Kruessel JS, Hirchenhain J. Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis. Int J Gynaecol Obstet. 2009;104(1):44–48. [PubMed] [Google Scholar]

4. Amin AF, Shaaban OM, Bediawy MA. N-acetyl cysteine for treatment of recurrent unexplained pregnancy loss. Reprod Biomed Online. 2008;17(5):722–726. [PubMed] [Google Scholar]

5. Elgindy EA, El-Huseiny AM, Mostafa MI, Gaballah AM, Ahmed TA. N-acetyl cysteine: could it be an effective adjuvant therapy in ICSI cycles?. A preliminary study. Reprod Biomed Online. 2010;20(6):789–796. [PubMed] [Google Scholar]

6. Agarwal A, Allamaneni SSR. Oxidants and antioxidants in human fertility. Middle East Fertil Soc J. 2004;9(3):187–197. [Google Scholar]

7. Wang Q, Hou Y, Yi D, Wang L, Ding B, Chen X, et al. Protective effects of N-acetyl cysteine on acetic acid-induced colitis in a porcine model. BMC Gastroenterol. 2013;13:133–133. [PMC free article][PubMed] [Google Scholar]

8. Nasr A. Effect of N-acetyl cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study. Reprod Biomed Online. 2010;20(3):403–409. [PubMed] [Google Scholar]

9. Moini A, Tadayon SH, Tehranian A, Mohammadi Yeganeh L, Akhoond MR, Salman Yazdi R. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Eendocrinol. 2012;28(8):590–593. [PubMed] [Google Scholar]

10. Moini A, Javanmard F, Eslami B, Aletaha N. Preval‎ence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. Iran J Reprod Med. 2012;10(2):127–130. [PMC free article][PubMed] [Google Scholar]

11. Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assist Reproduction Genet. 2009;26(2-3):123–127. [PMC free article] [PubMed] [Google Scholar]

12. Sekhon LH, Gupta S, Kim Y, Agarwal A. Female infertility and antioxidants. Curr Womens Health Rev. 2010;6:84–95. [Google Scholar]

13. Woods JR. Reactive oxygen species and preterm premature rupture of membranes a review. Placenta. 2001;22(Suppl A):S38–44. [PubMed] [Google Scholar]

14. Mercer BM, Goldenberg RL, Das A, Moawad AH, Iams JD, Meis PJ. The preterm prediction study: a clinical risk assessment system. Am J Obstet Gynecol. 1996;174(6):1885–1893. [PubMed] [Google Scholar]

15. American College of Obstetricians and Gynecologists. ACOG practice bulletin.Management of recurrent pregnancy loss.Number 24, February 2001.(Replaces Technical Bulletin Number 212, September 1995).American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002;78(2):179–190.[PubMed] [Google Scholar]

16. Poston L, Raijmakers MT. Trophoblast oxidative stress, antioxidants and pregnancy outcome--a review. Placenta. 2004;25(Suppl A):S72–78. [PubMed] [Google Scholar]

17. Mohammad Seyedhassani S, Houshmand M, Mehdi Kalantar S, Aflatoonian A, Modabber G, Hashemi Gorgi F, et al. BAX pro-apoptotic gene alterations in repeated pregnancy loss. Arch Med Sci. 2011;7(1):117–122. [PMC free article] [PubMed] [Google Scholar]

18. Zahraei M, Sheikhha MH, Kalantar SM, Ghasemi N, Jahaninejad T, Rajabi S, et al. The association of arylendosulfatase 1 (SULF1) gene polymorphism with recurrent miscarriage. J Assist Reprod Genet. 2014;31(2):157–161. [PMC free article] [PubMed] [Google Scholar]

19. Seyedhassani SM, Houshmand M, Kalantar SM, Modabber G, Aflatoonian A. No mitochondrial DNA deletions but more D-loop point mutations in repeated pregnancy loss. J Assist Reprod Genet. 2010;27(11):641–648. [PMC free article] [PubMed] [Google Scholar]

20. Harada M, Kishimoto K, Furuhashi T, Naito K, Nakashima Y, Kawaguchi Y, et al. Infertility observed in reproductive toxicity study of N-acetyl L-cysteine in rats. Biol Reprod. 2003;69(1):242–247. [PubMed] [Google Scholar]

21. Crowell C, Lyew RV, Givens M. Caring for the mother, concentrating on the fetus: intravenous N-acetyl cysteine in pregnancy. Am J Emerg Med. 2008;26(6):735–735. e1-735e2. [PubMed] [Google Scholar]

22. Green JL, Heard KJ, Reynolds KM, Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. West J Emerg Med. 2013;14(3):218–226.[PMC free article] [PubMed] [Google Scholar]

23. Beloosesky R, Gayle DA, Amidi F, Nunez SE, Babu J, Desai M, et al. N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. Am J Obstet Gynecol. 2006;194(1):268–273. [PubMed] [Google Scholar]

24. Paintlia MK, Paintlia AS, Singh AK, Singh I. Attenuation of lipopolysaccharide-induced inflammatory response and phospholipids metabolism at the feto-maternal interface by N-acetyl cysteine. Pediatr Res. 2008;64(4):334–339. [PMC free article] [PubMed] [Google Scholar]

25. Beloosesky R, Weiner Z, Khativ N, Maravi N, Mandel R, Boles J, et al. Prophylactic maternal n-acetylcysteine before lipopolysaccharide suppresses fetal inflammatory cytokine responses. Am J Obstet Gynecol. 2009;200(6):665–665. e1-665e1-5. [PubMed] [Google Scholar]

26. Cheraghi E, Mehranjani MS, Shariatzadeh MA, Nasr Esfahani MH, Ebrahimi Z. Co-administration of metformin and n-acetyl cysteine fails to improve clinical manifestations in pcos individual undergoing icsi. Int J Fertil Steril. 2014;8(2):119–128. [PMC free article] [PubMed] [Google Scholar]

27. Rizk AY, Bedaiwy MA, Al-Inany HG. Clomiphene-acetyl cysteine combination as a new protocol to a friendly IVF cycle. Middle East Fertil Soc J. 2005;10(2):130–134. [Google Scholar]

28. Larson M. Clinical recognition of N-acetyl cysteine in chronic bronchitis. Eur Respir Rev. 1992;2(7):5–8. [Google Scholar]

29. Tunek A. Possible mechanisms behind the anti-inflammatory effects of N-acetyl cysteine; is metabolism essential? Eur Respir Rev. 1992;2(7):35–38. [Google Scholar]

30. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16(2):253–262. [PubMed] [Google Scholar]

31. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo doseeffects: a review. Pulm Pharmacol Ther. 2007;20(1):9–22. [PubMed] [Google Scholar]

32. Jones DP, Maellaro E, Jiang S, Slater AF, Orrenius S. Effects of N-acetyl-L-cysteine on T-cell apoptosis are not mediated by increased cellular glutathione. Immunol Lett. 1995;45(3):205–209.[PubMed] [Google Scholar]

33. Cai T, Fassina G, Morini M, Aluigi MG, Masiello L, Fontanini G, et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest. 1999;79(9):1151–1159. [PubMed] [Google Scholar]

34. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Ciccolo A, Centorrino T, et al. Protective effects of N-acetyl cysteine on lung injury and red blood cell modification induced by carrageenan in the rat. FASEB J. 2001;15(7):1187–1200. [PubMed] [Google Scholar]

35. Kretzman NA, Chiela E, Matte U, Marroni N, Marroni CA. N-acetylcysteine improves antitumoural response of interferon alpha by NF-kB downregulation in liver cancer cells. Comp Hepatol. 2012;11(1):4–4. [PMC free article] [PubMed] [Google Scholar]

36. Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA Cancer J Clin. 1988;38(5):258–277. [PubMed] [Google Scholar]

37. Wanamarta AH, van Rijn J, Blank LE, Haveman J, van Zandwijk N, Joenje H. Effect of N-acetyl cysteine on the antiproliferative action of X-rays or bleomycin in cultured human lung tumor cells. J Cancer Res Clin Oncol. 1989;115(4):340–344. [PubMed] [Google Scholar]

38. Millea PJ. N-acetyl cysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265–269.[PubMed] [Google Scholar]

39. Moreno-Otero R, Trapero-Marugn M. Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol. 2010;16(15):1937–1938. [PMC free article] [PubMed] [Google Scholar]

40. Kerksick C, Willoughby D. The antioxidant role of glutathione and N-acetyl cysteine supplements and exerciseinduced oxidative stress. J Int Soc Sports Nutr. 2005;2(2):38–44. [PMC free article] [PubMed] [Google Scholar]

41. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007;4(2):143–150. [PubMed] [Google Scholar]

42. Khosravi M, Shohrati M, Falaknazi K. Does N-acetyl cysteine have a dose-dependent effect on plasma homocysteine concentration in patients undergoing hemodialysis? Int J Nephrol Urol. 2009;1(1):27–32.[Google Scholar]

43. Song DJ, Min MG, Miller M, Cho JY, Broide DH. Environmental tobacco smoke exposure does not prevent corticosteroids reducing inflammation, remodeling, and airway hyperreactivity in mice exposed to allergen. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L380–387. [PMC free article] [PubMed] [Google Scholar]

44. Li JJ, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG, et al. IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J Immunol. 2010;185(7):4401–4409. [PubMed] [Google Scholar]

45. Eftekhari P, Hajizadeh S, Raofy MR, Masjedi MR, Yang M, Hansbro N, et al. Preventive effect of N-acetylcysteine in a mouse model of steroid resistant acute exacerbation of asthma. Excli J. 2013;12:184–192. [PMC free article] [PubMed] [Google Scholar]

46. Blesa S, Cortijo J, Mata M, Serrano A, Closa D, Santangelo F, et al. Oral N-acetyl cysteine attenuates the rat pulmonary inflammatory response to antigen. Eur Respir J. 2003;21(3):394–400. [PubMed] [Google Scholar]

47. Blesa S, Cortijo J, Martinez-Losa M, Mata M, Seda E, Santangelo F, et al. Effectiveness of oral N-acetyl cysteine in a rat experimental model of asthma. Pharmacol Res. 2002;45(2):135–140. [PubMed] [Google Scholar]

48. Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol. 1999;56(12):1449–1452. [PubMed] [Google Scholar]

49. Perry G, Castellani RJ, Hirai K, Smith MA. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis. 1998;1(1):45–55. [PubMed] [Google Scholar]

50. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis. 2007;12(2):195–206. [PubMed] [Google Scholar]

51. Moreiraa PI, Carvalhob C, Zhuc X, Smithc MA, Perryd G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta. 2010;1802(1):2–10. [PubMed] [Google Scholar]

52. Hardas SS, Sultana R, Clark AM, Beckett TL, Szweda LI, Murphy MP, et al. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol. 2013;1:80–85. [PMC free article] [PubMed] [Google Scholar]

53. Kerksick C, Willoughby D. The Antioxidant role of glutathione and N-acetyl cysteine supplements and exerciseinduced oxidative stress. J Int Soc Sports Nutr. 2005;2:38–44. [PMC free article] [PubMed] [Google Scholar]

54. Agid Y, Ruberg M, Javoy-Agid F, Hirsch E, Raisman-Vozari R, Vyas S, et al. Are dopaminergic neurons selectively vulnerable to Parkinson’s disease? Adv Neurol. 1993;60:148–164. [PubMed] [Google Scholar]

55. Veldman BA, Wijn AM, Knoers N, Praamstra P, Horstink MW. Genetic and environmental risk factors in Parkinson’s disease. Clin Neurol Neurosurg. 1998;100(1):15–26. [PubMed] [Google Scholar]

56. Williams AC, Smith ML, Waring RH, Ramsden DB. Idiopathic Parkinson’s disease: a genetic and environmental model. Adv Neurol. 1999;80:215–218. [PubMed] [Google Scholar]

57. Bowling AC, Mutisya EM, Walker LC, Price DL, Cork LC, Beal MF. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem. 1993;60(5):1964–1967. [PubMed] [Google Scholar]

58. Curti D, Giangare MC, Redolfi ME, Fugaccia I, Benzi G. Age-related modification of cytochrome c oxidase activity in discrete brain regions. Mech Ageing Dev. 1990;55(2):171–180. [PubMed] [Google Scholar]

59. Martinez-Banclocha MA. N-acetyl cysteine in the treatment of Parkinson’s disease.What are we waiting for? Med Hypotheses. 2012;79(1):8–12. [PubMed] [Google Scholar]

60. Shahripour RB, Harrigan MR, Alexandrov AV. N-acetyl cysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4(2):108–122. [PMC free article][PubMed] [Google Scholar]

61. Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14(8):855–866. [PMC free article] [PubMed] [Google Scholar]